SL-701: Phase I/II data

A Phase I/II trial in 22 patients with recurrent malignant glioma showed that SL-701 produced 2 durable complete responses, 1 of which is ongoing at 18 months in a patient with recurrent glioblastoma, and 2 partial responses. In recurrent glioblastoma patients, median overall survival (OS) was 12 months with 6- and 12-month OS rates of 80% and 46%, respectively. Additionally, 46% of recurrent glioblastoma patients (n=13) and 67% of recurrent anaplastic glioma patients (n=9) had tumor shrinkage or stable disease. SL-701 was well tolerated with injection-site reactions, transient fatigues and chills reported as the most common adverse events. Data were presented at the American Society of Clinical Oncology meeting in Chicago. ...